NZ722342A - Human antibodies to pd-1 - Google Patents
Human antibodies to pd-1Info
- Publication number
- NZ722342A NZ722342A NZ722342A NZ72234215A NZ722342A NZ 722342 A NZ722342 A NZ 722342A NZ 722342 A NZ722342 A NZ 722342A NZ 72234215 A NZ72234215 A NZ 72234215A NZ 722342 A NZ722342 A NZ 722342A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibodies
- antibody
- binding
- amino acid
- antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461930576P | 2014-01-23 | 2014-01-23 | |
| US201462014181P | 2014-06-19 | 2014-06-19 | |
| PCT/US2015/012589 WO2015112800A1 (en) | 2014-01-23 | 2015-01-23 | Human antibodies to pd-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ722342A true NZ722342A (en) | 2022-05-27 |
Family
ID=52462456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ722342A NZ722342A (en) | 2014-01-23 | 2015-01-23 | Human antibodies to pd-1 |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9987500B2 (enExample) |
| EP (2) | EP3097119B1 (enExample) |
| JP (5) | JP6425730B2 (enExample) |
| KR (2) | KR102337042B1 (enExample) |
| CN (2) | CN113248614A (enExample) |
| AU (1) | AU2015209233B2 (enExample) |
| BR (1) | BR122022010183B1 (enExample) |
| CA (2) | CA3207270A1 (enExample) |
| CL (1) | CL2016001871A1 (enExample) |
| CY (1) | CY1124747T1 (enExample) |
| DK (1) | DK3097119T3 (enExample) |
| EA (1) | EA034770B8 (enExample) |
| ES (1) | ES2888224T3 (enExample) |
| HR (1) | HRP20211794T1 (enExample) |
| HU (1) | HUE056332T2 (enExample) |
| IL (2) | IL246818B (enExample) |
| LT (1) | LT3097119T (enExample) |
| MX (3) | MX385545B (enExample) |
| MY (1) | MY176475A (enExample) |
| NZ (1) | NZ722342A (enExample) |
| PH (1) | PH12016501330B1 (enExample) |
| PL (1) | PL3097119T3 (enExample) |
| PT (1) | PT3097119T (enExample) |
| RS (1) | RS62507B1 (enExample) |
| SG (1) | SG11201605482SA (enExample) |
| SI (1) | SI3097119T1 (enExample) |
| SM (1) | SMT202100669T1 (enExample) |
| TW (1) | TWI681969B (enExample) |
| UA (1) | UA122666C2 (enExample) |
| UY (1) | UY35964A (enExample) |
| WO (1) | WO2015112800A1 (enExample) |
Families Citing this family (607)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| CA2766272C (en) | 2009-06-26 | 2021-02-09 | Soricimed Biopharma Inc. | Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery |
| PL3409278T3 (pl) | 2011-07-21 | 2021-02-22 | Sumitomo Pharma Oncology, Inc. | Heterocykliczne inhibitory kinazy białkowej |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| KR102243062B1 (ko) | 2013-05-02 | 2021-04-21 | 아납티스바이오, 아이엔씨. | 예정된 사멸-1에 대한 항체 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| ES2746805T3 (es) | 2013-12-12 | 2020-03-06 | Shanghai hengrui pharmaceutical co ltd | Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| DK3099717T3 (da) | 2014-01-31 | 2019-07-01 | Novartis Ag | Antistofmolekyler med tim-3 og anvendelser deraf |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
| US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
| WO2017042633A2 (en) * | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| ES3040431T3 (en) | 2014-03-12 | 2025-10-31 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
| TWI777174B (zh) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| US9982052B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| US9982053B2 (en) | 2014-08-05 | 2018-05-29 | MabQuest, SA | Immunological reagents |
| EP3191126B1 (en) | 2014-09-13 | 2020-05-13 | Novartis AG | Combination therapies of alk inhibitors |
| AU2015350075B2 (en) | 2014-11-17 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using CD3xCD20 bispecific antibody |
| ES2905615T3 (es) * | 2014-11-20 | 2022-04-11 | Promega Corp | Sistemas y métodos para evaluar moduladores de puntos de control inmunitario |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| KR102610592B1 (ko) | 2015-03-30 | 2023-12-07 | 주식회사 에스티큐브 | 당화 pd-l1에 특이적인 항체 및 그의 사용 방법 |
| US10556952B2 (en) | 2015-03-30 | 2020-02-11 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to Fc gamma receptors |
| US11933786B2 (en) | 2015-03-30 | 2024-03-19 | Stcube, Inc. | Antibodies specific to glycosylated PD-L1 and methods of use thereof |
| CN116327915A (zh) * | 2015-04-03 | 2023-06-27 | 佐马技术有限公司 | 使用TGF-β抑制剂和PD-1抑制剂治疗癌症 |
| MX2017014822A (es) | 2015-05-18 | 2018-04-30 | Tcr2 Therapeutics Inc | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. |
| CN111349118B (zh) | 2015-05-18 | 2023-08-22 | 住友制药肿瘤公司 | 具有增加的生物利用度的阿伏西地前药 |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| TWI870335B (zh) | 2015-06-12 | 2025-01-21 | 美商宏觀基因股份有限公司 | 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用 |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| CN116059219A (zh) | 2015-07-16 | 2023-05-05 | 比奥克斯塞尔医疗股份有限公司 | 一种使用免疫调节治疗癌症的新颖方法 |
| HUE055207T2 (hu) | 2015-07-30 | 2021-11-29 | Macrogenics Inc | PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására |
| TWI899515B (zh) | 2015-08-04 | 2025-10-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| JP2018526989A (ja) | 2015-08-07 | 2018-09-20 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Ｌａｇ−３およびｐｄ−１に特異的な新規融合ポリペプチド |
| MY187739A (en) * | 2015-08-11 | 2021-10-18 | Wuxi Biologics Cayman Inc | Novel anti-pd-1 antibodies |
| AR105654A1 (es) * | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| CN114605548A (zh) * | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| TWI784917B (zh) | 2015-09-23 | 2022-11-21 | 美商再生元醫藥公司 | 最優化抗ｃｄ３雙特異性抗體及其用途 |
| CA2999756A1 (en) * | 2015-09-24 | 2017-03-30 | The University Of North Carolina At Chapel Hill | Methods and compositions for reducing metastases |
| HK1251158A1 (zh) * | 2015-09-29 | 2019-01-25 | 细胞基因公司 | Pd-1结合蛋白及其使用方法 |
| US10981991B2 (en) | 2015-09-29 | 2021-04-20 | Shanghai Zhangjiang Biotechnology Co., Ltd. | PD-1 antibodies and uses thereof |
| US12030942B2 (en) | 2015-10-02 | 2024-07-09 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
| SMT202100506T1 (it) | 2015-10-02 | 2021-11-12 | Hoffmann La Roche | Anticorpi bispecifici specifici per pd1 e tim3 |
| SG10201912943RA (en) | 2015-10-02 | 2020-02-27 | Symphogen As | Anti-pd-1 antibodies and compositions |
| CN108136010A (zh) | 2015-10-08 | 2018-06-08 | 宏观基因有限公司 | 用于治疗癌症的联合疗法 |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| SMT202200118T1 (it) * | 2015-11-03 | 2022-05-12 | Janssen Biotech Inc | Anticorpi che legano specificamente pd-1 e loro usi |
| SG11201804178YA (en) | 2015-11-18 | 2018-06-28 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
| CN106699889A (zh) * | 2015-11-18 | 2017-05-24 | 礼进生物医药科技（上海）有限公司 | 抗pd-1抗体及其治疗用途 |
| US10858432B2 (en) | 2015-12-02 | 2020-12-08 | Stcube, Inc. | Antibodies specific to glycosylated PD-1 and methods of use thereof |
| EA201891178A1 (ru) | 2015-12-14 | 2019-01-31 | Макродженикс, Инк. | Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения |
| US10392442B2 (en) | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
| MA44146B1 (fr) * | 2015-12-22 | 2023-10-31 | Regeneron Pharma | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer |
| CN105669864B (zh) * | 2015-12-23 | 2018-10-16 | 杭州尚健生物技术有限公司 | 抗人程序性死亡受体1抗体及其制备方法和用途 |
| EP3405499A4 (en) * | 2016-01-21 | 2020-03-18 | The Board of Trustees of the Leland Stanford Junior University | TREATMENT OF CANCER WITH COMBINATIONS OF IMMUNOREGULATORS |
| US10294299B2 (en) | 2016-01-22 | 2019-05-21 | MabQuest SA | Immunological reagents |
| US11214617B2 (en) | 2016-01-22 | 2022-01-04 | MabQuest SA | Immunological reagents |
| EP3408671B1 (en) * | 2016-01-25 | 2023-11-01 | F. Hoffmann-La Roche AG | Methods for assaying t-cell dependent bispecific antibodies |
| EP3416982A1 (en) | 2016-02-17 | 2018-12-26 | Novartis AG | Tgfbeta 2 antibodies |
| US10537633B2 (en) | 2016-03-04 | 2020-01-21 | Jn Biosciences Llc | Antibodies to TIGIT |
| US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
| WO2017165681A1 (en) * | 2016-03-24 | 2017-09-28 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| WO2017172733A1 (en) * | 2016-03-28 | 2017-10-05 | The Regents Of The University Of California | Anti-ryk antibodies and methods of using the same |
| JP7572146B2 (ja) | 2016-03-29 | 2024-10-23 | エスティーキューブ アンド カンパニー，インコーポレイテッド | グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法 |
| ES2973870T3 (es) | 2016-03-29 | 2024-06-24 | Univ Texas | Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos |
| JP7082065B2 (ja) | 2016-05-02 | 2022-06-07 | テトラジェネティクス， インコーポレイテッド | 抗Ｋｖ１．３抗体ならびにその産生方法および使用方法 |
| TWI786044B (zh) * | 2016-05-13 | 2022-12-11 | 美商再生元醫藥公司 | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 |
| JP7175198B2 (ja) | 2016-06-02 | 2022-11-18 | ブリストル－マイヤーズ スクイブ カンパニー | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ－１遮断 |
| FI3464368T3 (fi) | 2016-06-02 | 2023-09-12 | Bristol Myers Squibb Co | Anti-pd-1-vasta-aineen käyttö yhdistelmänä anti-cd30-vasta-aineen kanssa lymfooman hoitamisessa |
| EP3988570A1 (en) | 2016-06-03 | 2022-04-27 | Bristol-Myers Squibb Company | Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer |
| CN109475634A (zh) | 2016-06-03 | 2019-03-15 | 百时美施贵宝公司 | 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体 |
| EP3464369A1 (en) | 2016-06-03 | 2019-04-10 | Bristol-Myers Squibb Company | Anti-pd-1 antibody for use in a method of treating a tumor |
| US20200255524A1 (en) * | 2016-06-07 | 2020-08-13 | Macrogenics, Inc. | Combination therapy |
| WO2017214182A1 (en) * | 2016-06-07 | 2017-12-14 | The United States Of America. As Represented By The Secretary, Department Of Health & Human Services | Fully human antibody targeting pdi for cancer immunotherapy |
| RU2018146886A (ru) * | 2016-06-10 | 2020-07-10 | Новартис Аг | Пути терапевтического применения ингибитора c-raf |
| KR102495601B1 (ko) | 2016-06-10 | 2023-02-06 | 리제너론 파마슈티칼스 인코포레이티드 | 항-gitr 항체 및 그것의 사용 |
| EP3468581A1 (en) | 2016-06-13 | 2019-04-17 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| US11406975B2 (en) | 2016-07-18 | 2022-08-09 | President And Fellows Of Harvard College | Human lymphoid tissue-on-chip |
| JP2019528251A (ja) | 2016-07-20 | 2019-10-10 | エスティーキューブ，インコーポレイテッド | グリコシル化ｐｄ−ｌ１に結合する抗体の組合せを使用するがんの処置および治療の方法 |
| NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CA3032783C (en) * | 2016-08-05 | 2022-05-31 | Y-Biologics Inc. | Antibody to programmed cell death 1 (pd-1) and use thereof |
| WO2018026248A1 (ko) * | 2016-08-05 | 2018-02-08 | 주식회사 와이바이오로직스 | 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도 |
| EP3497128A2 (en) | 2016-08-09 | 2019-06-19 | Kymab Limited | Anti-icos antibodies |
| MA45999A (fr) | 2016-08-22 | 2019-06-26 | Arbutus Biopharma Corp | Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b |
| CN106977602B (zh) | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
| CN106967172B (zh) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| AU2017329024A1 (en) | 2016-09-19 | 2019-03-21 | Celgene Corporation | Methods of treating immune disorders using pd-1 binding proteins |
| WO2018053401A1 (en) | 2016-09-19 | 2018-03-22 | Celgene Corporation | Methods of treating vitiligo using pd-1 binding proteins |
| AU2017336867B2 (en) | 2016-09-29 | 2024-03-14 | Beijing Hanmi Pharmaceutical Co., Ltd. | Heterodimeric immunoglobulin constructs and preparation methods thereof |
| MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
| KR20240019398A (ko) | 2016-10-28 | 2024-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법 |
| EP3666794A1 (en) | 2016-11-01 | 2020-06-17 | AnaptysBio, Inc. | Antibodies directed against programmed death- 1 (pd-1) |
| HRP20211703T1 (hr) | 2016-11-02 | 2022-02-04 | Jounce Therapeutics, Inc. | Protutijela protiv pd-1 i njihova upotreba |
| WO2018085555A1 (en) | 2016-11-03 | 2018-05-11 | Bristol-Myers Squibb Company | Activatable anti-ctla-4 antibodies and uses thereof |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| CN110312523B (zh) * | 2016-11-08 | 2024-04-26 | 齐鲁皮吉特湾生物治疗有限公司 | 抗pd1和抗ctla4抗体 |
| CA3043652A1 (en) | 2016-11-18 | 2018-05-24 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same |
| EP3541841B1 (en) * | 2016-11-18 | 2024-09-11 | Les Laboratoires Servier | Anti-pd-1 antibodies and compositions |
| US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| EP3544996A2 (en) | 2016-11-22 | 2019-10-02 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| FI3548515T3 (fi) * | 2016-12-01 | 2026-03-04 | Regeneron Pharma | Radioleimattuja anti-PD-L1-vasta-aineita immuno-PET-kuvantamiseen |
| CN118634323A (zh) | 2016-12-07 | 2024-09-13 | 艾吉纳斯公司 | 抗体和其使用方法 |
| WO2018107178A1 (en) | 2016-12-09 | 2018-06-14 | Regeneron Pharmaceuticals, Inc. | Systems and methods for sequencing t cell receptors and uses thereof |
| WO2018119474A2 (en) * | 2016-12-23 | 2018-06-28 | Remd Biotherapeutics, Inc. | Immunotherapy using antibodies that bind programmed death 1 (pd-1) |
| CN106674209B (zh) * | 2016-12-23 | 2020-03-06 | 深圳先进技术研究院 | 程序性死亡受体1基因抑制剂及其制备方法与应用 |
| CN108203464B (zh) * | 2016-12-25 | 2021-07-20 | 南京金斯瑞生物科技有限公司 | 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-1抗体 |
| CN113480530A (zh) | 2016-12-26 | 2021-10-08 | 阿里根公司 | 芳香烃受体调节剂 |
| CN109071656B (zh) | 2017-01-05 | 2021-05-18 | 璟尚生物制药公司 | 检查点调节物拮抗剂 |
| BR112019014187A2 (pt) | 2017-01-09 | 2020-02-11 | Tesaro, Inc. | Métodos de tratamento de câncer com anticorpos anti-pd-1 |
| WO2018134279A1 (en) | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptides specific for lag-3 and pd-1 |
| AR110904A1 (es) * | 2017-01-20 | 2019-05-15 | Sanofi Sa | ANTICUERPOS ANTI-TGF-b Y SU USO |
| AR110755A1 (es) | 2017-01-20 | 2019-05-02 | Genzyme Corp | Anticuerpos dirigidos a hueso |
| WO2018133842A1 (zh) | 2017-01-20 | 2018-07-26 | 大有华夏生物医药集团有限公司 | 人程序性死亡受体pd-1的单克隆抗体及其片段 |
| WO2018134784A1 (en) | 2017-01-20 | 2018-07-26 | Novartis Ag | Combination therapy for the treatment of cancer |
| TW202506185A (zh) * | 2017-01-20 | 2025-02-16 | 法商賽諾菲公司 | 抗TGF-β抗體及其用途 |
| EA201991729A1 (ru) * | 2017-01-20 | 2019-12-30 | Санофи | Антитела к tgf-бета и их применение |
| PT3579874T (pt) | 2017-02-10 | 2021-10-07 | Novartis Ag | 1-(4-amino-5-bromo-6-(1h-pirazol-1-il)pirimidin-2-il)-1hpirazol- 4-ol e sua utilização no tratamento de cancro |
| AU2018219909B2 (en) | 2017-02-10 | 2025-02-27 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-LAG3 antibodies for immuno-PET imaging |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| IL321717A (en) | 2017-02-21 | 2025-08-01 | Regeneron Pharma | Anti-PD-1 antibodies for the treatment of lung cancer |
| SG11201907753TA (en) | 2017-02-24 | 2019-09-27 | Macrogenics Inc | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof |
| WO2018160540A1 (en) | 2017-02-28 | 2018-09-07 | Sanofi | Therapeutic rna |
| EP3589652B1 (en) | 2017-03-04 | 2024-12-25 | Xiangtan Tenghua Bioscience | Recombinant antibodies to programmed death 1 (pd-1) and uses therefor |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| CA3055984A1 (en) * | 2017-03-29 | 2018-10-04 | Celgene Corporation | Formulations comprising pd-1 binding proteins and methods of making thereof |
| IL269026B2 (en) | 2017-03-31 | 2024-12-01 | Bristol Myers Squibb Co | Anti-pd-1 antibodies for treating tumors in high tumor mutational burden (tmb) patients |
| AU2018243104B2 (en) * | 2017-04-01 | 2024-11-14 | Beijing Hanmi Pharm. Co., Ltd. | Anti-PD-L1/anti-PD-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof |
| KR20190121816A (ko) | 2017-04-03 | 2019-10-28 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
| JP2020515637A (ja) | 2017-04-03 | 2020-05-28 | オンコロジー、インコーポレイテッド | 免疫腫瘍剤を伴うｐｓ標的化抗体を用いる癌の治療方法 |
| PL3606955T3 (pl) | 2017-04-05 | 2025-02-24 | F. Hoffmann-La Roche Ag | Przeciwciała dwuswoiste swoiście wiążące się z PD1 i LAG3 |
| CA3185303A1 (en) | 2017-04-05 | 2018-10-11 | Symphogen A/S | Combination therapies targeting pd-a, tim-3, and lag-3 |
| US11603407B2 (en) * | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| AR111760A1 (es) | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
| JP2020520985A (ja) * | 2017-05-22 | 2020-07-16 | オンコイミューン， インコーポレイテッド | がん療法における免疫関連有害事象の治療のための可溶性ｃｄ２４の使用方法 |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| KR102713203B1 (ko) | 2017-05-30 | 2024-10-10 | 브리스톨-마이어스 스큅 컴퍼니 | Lag-3 양성 종양의 치료 |
| US20210340250A1 (en) | 2017-05-30 | 2021-11-04 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
| KR20240155979A (ko) | 2017-05-30 | 2024-10-29 | 브리스톨-마이어스 스큅 컴퍼니 | 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물 |
| JOP20190279A1 (ar) | 2017-05-31 | 2019-11-28 | Novartis Ag | الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة |
| WO2018223040A1 (en) | 2017-06-01 | 2018-12-06 | Bristol-Myers Squibb Company | Methods of treating a tumor using an anti-pd-1 antibody |
| AU2018282094B2 (en) | 2017-06-05 | 2024-06-27 | Janssen Biotech, Inc. | Antibodies that specifically bind PD-1 and methods of use |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| KR20200019865A (ko) | 2017-06-22 | 2020-02-25 | 노파르티스 아게 | 암 치료에 사용하기 위한 il-1베타 결합 항체 |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| CN110785187B (zh) | 2017-06-22 | 2024-04-05 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| EP3645740A4 (en) * | 2017-06-25 | 2021-08-18 | Systimmune, Inc. | ANTI-PD-1 ANTIBODIES AND METHOD OF MANUFACTURING AND USE |
| US20200223924A1 (en) | 2017-06-27 | 2020-07-16 | Novartis Ag | Dosage regimens for anti-tim-3 antibodies and uses thereof |
| EP3421494A1 (en) | 2017-06-29 | 2019-01-02 | Sanofi | Use of isatuximab in combination with an anti-pd-1 antibody |
| CN114075269A (zh) | 2017-07-06 | 2022-02-22 | 菲仕兰坎皮纳荷兰私人有限公司 | 用于制备糖蛋白的细胞培养工艺 |
| CN111793060B (zh) | 2017-07-14 | 2023-06-06 | 先天肿瘤免疫公司 | Nlrp3调节剂 |
| CN111163798A (zh) | 2017-07-20 | 2020-05-15 | 诺华股份有限公司 | 用于抗lag-3抗体的给药方案及其用途 |
| IL316355A (en) * | 2017-07-24 | 2024-12-01 | Regeneron Pharma | Anti-CD8 antibodies and their uses |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| EP3658565B1 (en) | 2017-07-28 | 2022-11-09 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019027847A1 (en) * | 2017-07-29 | 2019-02-07 | University Of Southern California | SYNTHETIC EXTRACELLULAR VESICLES FOR NEW THERAPIES |
| ES2910969T3 (es) | 2017-08-03 | 2022-05-17 | Amgen Inc | Muteínas de interleucina-21 y métodos de tratamiento |
| WO2019025545A1 (en) | 2017-08-04 | 2019-02-07 | Genmab A/S | BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE |
| WO2019046496A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
| WO2019046498A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
| JP7208225B2 (ja) | 2017-08-31 | 2023-01-18 | ブリストル－マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
| US11021540B2 (en) * | 2017-09-07 | 2021-06-01 | Augusta University Research Institute, Inc. | Antibodies to programmed cell death protein 1 |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| KR20200059243A (ko) | 2017-09-20 | 2020-05-28 | 리제너론 파마슈티칼스 인코포레이티드 | 패신저 유전자 돌연변이 부담이 높은 종양을 가진 환자에 대한 면역 치료요법 |
| WO2019067913A1 (en) | 2017-09-29 | 2019-04-04 | Bristol-Myers Squibb Company | COMPOSITIONS AND METHODS OF TREATING CANCER |
| WO2019074887A1 (en) | 2017-10-10 | 2019-04-18 | Bristol-Myers Squibb Company | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
| KR20200064132A (ko) | 2017-10-15 | 2020-06-05 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| KR102747388B1 (ko) | 2017-10-16 | 2024-12-26 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
| WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
| KR20200074993A (ko) | 2017-11-03 | 2020-06-25 | 노파르티스 아게 | 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체 |
| WO2019090263A1 (en) | 2017-11-06 | 2019-05-09 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| SG11202003626RA (en) | 2017-11-06 | 2020-05-28 | Bristol Myers Squibb Co | Methods of treating a tumor |
| JP2021502405A (ja) * | 2017-11-08 | 2021-01-28 | エピアクシス セラピューティクス プロプライエタリー リミテッド | 免疫原性組成物及びその使用 |
| MX2020004756A (es) | 2017-11-16 | 2020-08-20 | Novartis Ag | Terapias de combinacion. |
| JP2021503498A (ja) | 2017-11-20 | 2021-02-12 | アリアジェン，インコーポレイテッド | アリール炭化水素受容体（ａｈｒ）調節剤としてのインドール化合物 |
| CA3083949A1 (en) | 2017-11-30 | 2020-06-06 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CN109912577B (zh) * | 2017-12-12 | 2021-10-22 | 深圳先进技术研究院 | 用于抑制eb病毒相关肿瘤的化合物及其制备方法和用途 |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| CN111479618B (zh) | 2017-12-22 | 2022-08-02 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
| CN112218651A (zh) | 2018-01-08 | 2021-01-12 | 诺华公司 | 用于与嵌合抗原受体疗法组合的免疫增强rna |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| US20210363242A1 (en) | 2018-01-16 | 2021-11-25 | Bristol-Myers Squibb Company | Methods of treating cancer with antibodies against tim3 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CN111629731A (zh) | 2018-01-22 | 2020-09-04 | 百时美施贵宝公司 | 治疗癌症的组合物和方法 |
| WO2019144126A1 (en) | 2018-01-22 | 2019-07-25 | Pascal Biosciences Inc. | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells |
| US20210038659A1 (en) | 2018-01-31 | 2021-02-11 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| KR20200115485A (ko) | 2018-01-31 | 2020-10-07 | 리제너론 파마슈티칼스 인코포레이티드 | 약물 생성물 불순물을 특성화하기 위한 시스템 및 방법 |
| TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| KR102171766B1 (ko) * | 2018-02-02 | 2020-10-29 | 주식회사 뉴라클제네틱스 | Pd-l1 결합력이 증대된 pd-1 변이체 |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| EP3752203A1 (en) | 2018-02-13 | 2020-12-23 | Novartis AG | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| US10519187B2 (en) | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| GB201802573D0 (en) * | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| US12460270B2 (en) | 2018-02-28 | 2025-11-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| MY199140A (en) | 2018-02-28 | 2023-10-17 | Ap Biosciences Inc | Bifunctional proteins combining checkpoint blockade for targeted therapy |
| WO2019173587A1 (en) | 2018-03-08 | 2019-09-12 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| BR112020015291B1 (pt) | 2018-03-19 | 2023-09-26 | Regeneron Pharmaceuticals, Inc | Tampão de amostra de eletroforese aquoso, método para identificar contaminantes ou impurezas em uma amostra de fármaco proteico, e, kit |
| KR20200135447A (ko) | 2018-03-22 | 2020-12-02 | 카이레스 아게 | 길항성 pd-1, pd-l1 및 lag-3 결합 단백질 |
| BR112020018539A2 (pt) | 2018-03-23 | 2020-12-29 | Bristol-Myers Squibb Company | Anticorpos contra mica e/ou micb e usos dos mesmos |
| EP3768277A1 (en) * | 2018-03-23 | 2021-01-27 | Isr Immune System Regulation Holding Ab (Publ) | Combinations of macrolide compounds and immune checkpoint inhibitors |
| CN108546297B (zh) * | 2018-03-29 | 2019-08-02 | 中国人民解放军军事科学院军事医学研究院 | 针对pd-1的单克隆抗体及其应用 |
| KR20200139724A (ko) | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| WO2019195452A1 (en) | 2018-04-04 | 2019-10-10 | Bristol-Myers Squibb Company | Anti-cd27 antibodies and uses thereof |
| US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
| CN109336975B (zh) * | 2018-04-18 | 2022-05-13 | 中国科学院微生物研究所 | 一种靶向pd-1的肿瘤抑制性抗体及其应用 |
| JP7351850B2 (ja) | 2018-04-25 | 2023-09-27 | イネイト・テューマー・イミュニティ・インコーポレイテッド | Ｎｌｒｐ３修飾因子 |
| CN110404066B (zh) * | 2018-04-28 | 2022-06-17 | 齐鲁制药有限公司 | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 |
| CN108840932B (zh) * | 2018-04-28 | 2022-03-29 | 中国科学院微生物研究所 | 一种pd-1特异性抗体及其抗肿瘤应用 |
| BR112020022145A2 (pt) | 2018-05-04 | 2021-01-26 | Merck Patent Gmbh | inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| JP2021522835A (ja) | 2018-05-14 | 2021-09-02 | イムノコア リミテッド | 二機能性結合ポリペプチド |
| EP3794039A4 (en) | 2018-05-17 | 2022-05-04 | Nanjing Leads Biolabs Co., Ltd. | PD-1 BINDING ANTIBODIES AND USE |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| TW202017569A (zh) | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | 用於抑制cd73之組合物及方法 |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| KR20250151605A (ko) | 2018-06-01 | 2025-10-21 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| CN120714023A (zh) | 2018-06-20 | 2025-09-30 | 因赛特公司 | 抗pd-1抗体及其用途 |
| CA3104098A1 (en) | 2018-06-21 | 2019-12-26 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
| TWI890661B (zh) | 2018-06-21 | 2025-07-21 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法 |
| AU2019288728A1 (en) | 2018-06-23 | 2021-01-14 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor |
| US11795206B2 (en) | 2018-06-24 | 2023-10-24 | Yunbiao Lu | Specific bifunctional BY-001 (active composition of homomultimer of chimeric protein pd-L1 / fc-gamma1) down regulates the activation of human immune cells and the use thereof |
| EP3813864A4 (en) | 2018-06-29 | 2022-07-20 | Gensun Biopharma Inc. | Antitumor antagonists |
| AU2019301070B2 (en) * | 2018-07-09 | 2025-09-11 | Precigen, Inc. | Fusion constructs and methods of using thereof |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| BR112021000673A2 (pt) | 2018-07-18 | 2021-04-20 | Genentech, Inc. | métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições |
| EP3823991A4 (en) * | 2018-07-19 | 2022-08-03 | Tayu Huaxia Biotech Medical Group Co., Ltd. | ANTI-PD-1 ANTIBODIES, DOSAGE FORMS AND USES THEREOF |
| WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
| SG11202100693UA (en) | 2018-07-26 | 2021-02-25 | Bristol Myers Squibb Co | Lag-3 combination therapy for the treatment of cancer |
| WO2020021061A1 (en) | 2018-07-26 | 2020-01-30 | Pieris Pharmaceuticals Gmbh | Humanized anti-pd-1 antibodies and uses thereof |
| CA3106563A1 (en) | 2018-07-26 | 2020-01-30 | Atyr Pharma, Inc. | Compositions and methods for treating nrp2-associated diseases |
| WO2020037094A1 (en) | 2018-08-16 | 2020-02-20 | Innate Tumor Immunity, Inc. | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
| WO2020037091A1 (en) | 2018-08-16 | 2020-02-20 | Innate Tumor Immunity, Inc. | Imidazo[4,5-c]quinoline derived nlrp3-modulators |
| KR102817037B1 (ko) | 2018-08-16 | 2025-06-04 | 인네이트 튜머 이뮤니티, 인코포레이티드 | 이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제 |
| WO2020041655A1 (en) | 2018-08-24 | 2020-02-27 | Sanofi | Therapeutic rna for solid tumor cancers |
| CN112218877B (zh) | 2018-08-27 | 2025-07-25 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| WO2020043683A1 (en) | 2018-08-27 | 2020-03-05 | Pieris Pharmaceuticals Gmbh | Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof |
| KR20210053816A (ko) | 2018-08-30 | 2021-05-12 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질 복합체를 특성화하기 위한 방법 |
| WO2020044252A1 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Dosage regimes for anti-m-csf antibodies and uses thereof |
| IL280875B2 (en) | 2018-08-31 | 2024-12-01 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| TW202024023A (zh) | 2018-09-03 | 2020-07-01 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| WO2020049534A1 (en) | 2018-09-07 | 2020-03-12 | Novartis Ag | Sting agonist and combination therapy thereof for the treatment of cancer |
| EP3864046A1 (en) | 2018-10-09 | 2021-08-18 | Bristol-Myers Squibb Company | Anti-mertk antibodies for treating cancer |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020079581A1 (en) | 2018-10-16 | 2020-04-23 | Novartis Ag | Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy |
| CA3117016A1 (en) | 2018-10-19 | 2020-04-23 | Bristol-Myers Squibb Company | Combination therapy for melanoma |
| US12479917B2 (en) | 2018-10-23 | 2025-11-25 | Bristol-Myers Squibb Company | Methods of treating NSCLC comprising administering platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody |
| US20230053449A1 (en) | 2018-10-31 | 2023-02-23 | Novartis Ag | Dc-sign antibody drug conjugates |
| KR20210091209A (ko) * | 2018-11-05 | 2021-07-21 | 머크 샤프 앤드 돔 코포레이션 | 암의 치료를 위한 항-tigit 항체의 투여 요법 |
| BR112021008795A2 (pt) * | 2018-11-13 | 2021-08-31 | Compass Therapeutics Llc | Construtos de ligação multiespecíficos contra moléculas de ponto de verificação e seus usos |
| EP3880186B1 (en) | 2018-11-14 | 2024-04-03 | Regeneron Pharmaceuticals, Inc. | Intralesional administration of pd-1 inhibitors for treating skin cancer |
| MY205758A (en) | 2018-11-16 | 2024-11-12 | Bristol Myers Squibb Co | Anti-nkg2a antibodies and uses thereof |
| WO2020106695A1 (en) | 2018-11-19 | 2020-05-28 | Ariagen, Inc. | Methods of treating cancer |
| EP3883610A4 (en) | 2018-11-20 | 2022-11-02 | Cornell University | MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN CANCER RADIATION THERAPY |
| TWI894130B (zh) | 2018-12-03 | 2025-08-21 | 美商艾澤西公司 | 包含抗191p4d12抗體藥物結合物之醫藥組合物及其使用方法 |
| JP7584418B2 (ja) | 2018-12-04 | 2024-11-15 | ブリストル－マイヤーズ スクイブ カンパニー | 多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法 |
| MX2021006544A (es) | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. |
| EP3666905A1 (en) * | 2018-12-11 | 2020-06-17 | Sanofi | E. coli positive for pks island as marker of positive response to anti-pd1 therapy in colorectal cancer |
| CN113195467A (zh) | 2018-12-11 | 2021-07-30 | 施万生物制药研发Ip有限责任公司 | 适用作alk5抑制剂的萘啶和喹啉衍生物 |
| KR20210104836A (ko) | 2018-12-19 | 2021-08-25 | 리제너론 파아마슈티컬스, 인크. | 이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도 |
| WO2020132091A2 (en) * | 2018-12-19 | 2020-06-25 | Humabs Biomed Sa | Antibodies that neutralize hepatitis b virus and uses thereof |
| KR20210104758A (ko) | 2018-12-19 | 2021-08-25 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-muc16 x 항-cd28 항체 및 이의 용도 |
| MX2021007392A (es) | 2018-12-20 | 2021-08-24 | Novartis Ag | Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona. |
| DK4285929T3 (da) | 2018-12-20 | 2025-12-22 | Humabs Biomed Sa | Kombinationsterapi mod hbv |
| MX390775B (es) * | 2018-12-21 | 2025-03-21 | Ose Immunotherapeutics | Anticuerpo humanizado anti-pd-1 humana |
| AU2019406840A1 (en) | 2018-12-21 | 2021-06-03 | Novartis Ag | Use of IL-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome |
| MX2021007271A (es) | 2018-12-21 | 2021-07-15 | Onxeo | Nuevas moleculas de acido nucleico conjugado y sus usos. |
| WO2020128637A1 (en) | 2018-12-21 | 2020-06-25 | Novartis Ag | Use of il-1 binding antibodies in the treatment of a msi-h cancer |
| EP3897613A1 (en) | 2018-12-21 | 2021-10-27 | Novartis AG | Use of il-1beta binding antibodies |
| US20220056123A1 (en) | 2018-12-21 | 2022-02-24 | Novartis Ag | Use of il-1beta binding antibodies |
| EP3899951A1 (en) | 2018-12-23 | 2021-10-27 | F. Hoffmann-La Roche AG | Tumor classification based on predicted tumor mutational burden |
| KR20210121046A (ko) * | 2018-12-27 | 2021-10-07 | 기가젠, 인코포레이티드 | 항-pd-1 결합 단백질 및 이의 사용 방법 |
| JP7373571B2 (ja) | 2019-01-14 | 2023-11-02 | イネイト・テューマー・イミュニティ・インコーポレイテッド | がん治療に用いるためのｎｌｒｐ３モジュレーターとしての置換キナゾリン |
| KR102865929B1 (ko) | 2019-01-14 | 2025-09-29 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
| MX2021008434A (es) | 2019-01-14 | 2021-09-23 | Genentech Inc | Metodos para tratar el cancer con un antagonista de union al eje de pd-1 y una vacuna de arn. |
| CN113301962A (zh) | 2019-01-14 | 2021-08-24 | 先天肿瘤免疫公司 | 用于治疗癌症的杂环nlrp3调节剂 |
| JP7506080B2 (ja) | 2019-01-14 | 2024-06-25 | イネイト・テューマー・イミュニティ・インコーポレイテッド | Ｎｌｒｐ３モジュレーター |
| IL284471B2 (en) | 2019-01-16 | 2025-01-01 | Regeneron Pharma | Methods for identifying free thiols in proteins |
| TWI850316B (zh) | 2019-01-21 | 2024-08-01 | 法商賽諾菲公司 | 用於晚期實性瘤癌症之治療性rna及抗pd1抗體 |
| WO2020160375A1 (en) | 2019-02-01 | 2020-08-06 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof |
| NZ778055A (en) | 2019-02-12 | 2025-11-28 | Sumitomo Pharma America Inc | Formulations comprising heterocyclic protein kinase inhibitors |
| KR20210126652A (ko) | 2019-02-12 | 2021-10-20 | 노파르티스 아게 | Tno155 및 pd-1 억제제를 포함하는 약제학적 조합물 |
| WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| BR112021015783A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos |
| SG11202108089SA (en) * | 2019-02-28 | 2021-08-30 | Regeneron Pharma | Administration of pd-1 inhibitors for treating skin cancer |
| SG11202109003QA (en) | 2019-03-06 | 2021-09-29 | Regeneron Pharma | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer |
| CN113631189A (zh) | 2019-03-13 | 2021-11-09 | 默沙东公司 | 包含ctla-4和pd-1封闭剂的抗癌联合治疗 |
| JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置 |
| WO2020198077A1 (en) | 2019-03-22 | 2020-10-01 | Sumitomo Dainippon Pharma Oncology, Inc. | Compositions comprising pkm2 modulators and methods of treatment using the same |
| EP3941941A1 (en) | 2019-03-22 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Egfr x cd28 multispecific antibodies |
| CN113891748A (zh) | 2019-03-28 | 2022-01-04 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
| CN113677402A (zh) | 2019-03-28 | 2021-11-19 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
| BR112021020225A2 (pt) | 2019-04-12 | 2021-12-07 | Vascular Biogenics Ltd | Métodos de terapia antitumoral |
| CN113906021A (zh) | 2019-04-15 | 2022-01-07 | 阿里根公司 | 手性吲哚化合物及其用途 |
| EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
| MX2021012692A (es) | 2019-04-19 | 2021-11-12 | Genentech Inc | Anticuerpos anti-mertk y sus metodos de uso. |
| WO2020231766A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| WO2020231713A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| EP3969908A1 (en) | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Improved competitive ligand binding assays |
| EP3969040A1 (en) | 2019-05-13 | 2022-03-23 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
| TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向ＭＡｄＣＡＭ之免疫耐受性 |
| CN113874036A (zh) | 2019-05-24 | 2021-12-31 | 辉瑞公司 | 使用cdk抑制剂的联合治疗 |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| CN114174537A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 细胞定位特征和组合疗法 |
| WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
| AU2020290971A1 (en) * | 2019-06-14 | 2021-12-23 | Dana-Farber Cancer Institute, Inc. | Antibodies against PD-1 and methods of use thereof |
| EP3986454A1 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody |
| CA3143634A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody |
| WO2020263312A1 (en) | 2019-06-28 | 2020-12-30 | Gensun Biopharma, Inc. | ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFβ1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD |
| CN114302878A (zh) | 2019-07-03 | 2022-04-08 | 大日本住友制药肿瘤公司 | 酪氨酸激酶非受体1(tnk1)抑制剂及其用途 |
| US20220251215A1 (en) * | 2019-07-03 | 2022-08-11 | Regeneron Pharmaceuticals, Inc. | Anti-new york esophageal squamous cell carcinoma 1 (ny-eso-1) antigen-binding proteins and methods of use thereof |
| EP3998081A4 (en) | 2019-07-05 | 2023-07-12 | Ono Pharmaceutical Co., Ltd. | TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN |
| CN114401988A (zh) * | 2019-07-09 | 2022-04-26 | 国家生物技术研究所公司 | 具有降低的免疫原性的抗体 |
| CA3152371A1 (en) * | 2019-08-01 | 2021-02-04 | Vaccinex, Inc. | Combined inhibition of semaphorin-4d and tgf.beta. and compositions therefor |
| US20220273718A1 (en) * | 2019-08-02 | 2022-09-01 | University Of Virginia Patent Foundation | Bispecific antibody targeting of t regulatory cells for treatment of inflammatory conditions |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| US20220306630A1 (en) | 2019-08-06 | 2022-09-29 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| JP7771749B2 (ja) | 2019-08-08 | 2025-11-18 | 小野薬品工業株式会社 | 二重特異性タンパク質 |
| US11629190B2 (en) | 2019-08-15 | 2023-04-18 | Oregon State University | Canine antibody therapeutic for treating cancer |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| WO2021053559A1 (en) | 2019-09-18 | 2021-03-25 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| WO2021055994A1 (en) | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
| EP4653865A3 (en) | 2019-09-24 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
| EP4034248A1 (en) | 2019-09-25 | 2022-08-03 | Bristol-Myers Squibb Company | Composite biomarker for cancer therapy |
| EP4034154A1 (en) | 2019-09-25 | 2022-08-03 | Seagen Inc. | Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers |
| AU2020370832A1 (en) | 2019-10-21 | 2022-05-19 | Novartis Ag | TIM-3 inhibitors and uses thereof |
| BR112022007376A2 (pt) | 2019-10-21 | 2022-07-05 | Novartis Ag | Terapias de combinação com venetoclax e inibidores de tim-3 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| WO2021087105A1 (en) | 2019-10-30 | 2021-05-06 | Duke University | Immunotherapy with combination therapy comprising an immunotoxin |
| IL292462A (en) * | 2019-11-04 | 2022-06-01 | Inovio Pharmaceuticals Inc | Combination therapy to treat brain cancer |
| EP4055153A4 (en) | 2019-11-04 | 2024-02-14 | Duke University | TREATMENT OF PRIMARY AND METASTASIC CANCER |
| JP2022553821A (ja) | 2019-11-05 | 2022-12-26 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍ－タンパク質アッセイおよびその使用 |
| WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
| WO2021092071A1 (en) | 2019-11-07 | 2021-05-14 | Oncxerna Therapeutics, Inc. | Classification of tumor microenvironments |
| CN115942973A (zh) | 2019-11-08 | 2023-04-07 | 百时美施贵宝公司 | 用于黑色素瘤的lag-3拮抗剂疗法 |
| EP4058435A1 (en) | 2019-11-13 | 2022-09-21 | Genentech, Inc. | Therapeutic compounds and methods of use |
| US20220395553A1 (en) | 2019-11-14 | 2022-12-15 | Cohbar, Inc. | Cxcr4 antagonist peptides |
| US20230000864A1 (en) | 2019-11-22 | 2023-01-05 | Sumitomo Pharma Oncology, Inc. | Solid dose pharmaceutical composition |
| EP4061809A1 (en) | 2019-11-22 | 2022-09-28 | Theravance Biopharma R&D IP, LLC | Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors |
| MX2022006236A (es) | 2019-11-25 | 2022-06-22 | Regeneron Pharma | Formulaciones de liberacion sostenida con emulsiones no acuosas. |
| TW202133887A (zh) | 2019-12-09 | 2021-09-16 | 美商西健公司 | 使用liv1-adc及pd-1拮抗劑之組合療法 |
| JP2023510108A (ja) | 2019-12-19 | 2023-03-13 | ブリストル－マイヤーズ スクイブ カンパニー | Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ |
| TW202135859A (zh) | 2019-12-20 | 2021-10-01 | 瑞士商諾華公司 | 組合療法 |
| WO2021121373A1 (zh) * | 2019-12-20 | 2021-06-24 | 广东菲鹏制药股份有限公司 | 抗人程序死亡因子-1单克隆抗体 |
| EP4087842A1 (en) | 2020-01-10 | 2022-11-16 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| MX2022008763A (es) | 2020-01-17 | 2022-07-27 | Novartis Ag | Combinacion que comprende un inhibidor de tim-3 y un agente hipometilante para usarse en el tratamiento del sindrome mielodisplasico o leucemia mielomonocitica cronica. |
| KR102544013B1 (ko) | 2020-01-21 | 2023-06-19 | 리제너론 파마슈티칼스 인코포레이티드 | 당질화된 단백질의 전기영동을 위한 탈당질화 방법 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| KR20220133996A (ko) | 2020-01-30 | 2022-10-05 | 오엔에이 테라퓨틱스 에스.엘. | 암 및 암 전이를 치료하기 위한 병용 요법 |
| EP4096708A1 (en) | 2020-01-31 | 2022-12-07 | Genentech, Inc. | Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine |
| EP4100426A1 (en) | 2020-02-06 | 2022-12-14 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
| CN113244385A (zh) * | 2020-02-07 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗恶性肿瘤中的用途 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| AU2021225491A1 (en) | 2020-02-28 | 2022-10-20 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, an Erk inhibitor and a RAF inhibitor |
| JP2023516724A (ja) | 2020-03-06 | 2023-04-20 | オーエヌエー セラピューティクス エセ．エレ． | 抗ｃｄ３６抗体及び癌を治療するためのそれらの使用 |
| BR112022017637A2 (pt) | 2020-03-06 | 2022-11-08 | Celgene Quanticel Res Inc | Métodos de tratamento do câncer de pulmão de células pequenas e/ou câncer de pulmão de células não pequenas |
| CN115244084A (zh) | 2020-03-06 | 2022-10-25 | 瑞泽恩制药公司 | 抗gitr抗体及其用途 |
| TW202202521A (zh) | 2020-03-23 | 2022-01-16 | 美商必治妥美雅史谷比公司 | 用於治療癌症之抗ccr8抗體 |
| US20230107609A1 (en) * | 2020-03-26 | 2023-04-06 | Cureimmune Therapeutics Inc. | Anti-pd-1 antibodies and methods of use |
| WO2021191870A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| EP4126824A1 (en) | 2020-03-31 | 2023-02-08 | Theravance Biopharma R&D IP, LLC | Substituted pyrimidines and methods of use |
| WO2021209049A1 (zh) * | 2020-04-16 | 2021-10-21 | 南通壹宸生物医药科技有限公司 | 一种pd-1突变体多肽及其制备和用途 |
| AU2021260982B2 (en) | 2020-04-21 | 2024-03-28 | Novartis Ag | Dosing regimen for treating a disease modulated by CSF-1R |
| IL297329A (en) | 2020-04-22 | 2022-12-01 | Merck Sharp & Dohme Llc | Dimeric interleukin-2 beta gamma receptor-biased human interleukin-2 conjugates conjugated to soluble non-peptide polymers. |
| PH12022553181A1 (en) | 2020-05-26 | 2024-03-04 | Boehringer Ingelheim Int | Anti-pd-1 antibodies |
| KR20230015954A (ko) * | 2020-05-26 | 2023-01-31 | 리제너론 파마슈티칼스 인코포레이티드 | Pd-1 억제제의 투여에 의한 자궁경부암의 치료 방법 |
| US20230203157A1 (en) * | 2020-05-27 | 2023-06-29 | Dana-Farber Cancer Institute, Inc. | Bispecific molecules for selectively modulating t cells |
| CR20220611A (es) | 2020-06-02 | 2023-06-07 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
| US20210387983A1 (en) | 2020-06-10 | 2021-12-16 | Theravance Biopharma R&D Ip, Llc | Crystalline alk5 inhibitors and uses thereof |
| TW202214857A (zh) | 2020-06-19 | 2022-04-16 | 法商昂席歐公司 | 新型結合核酸分子及其用途 |
| WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| JP2023531537A (ja) | 2020-06-30 | 2023-07-24 | メンドゥス・ベスローテン・フェンノートシャップ | 卵巣癌ワクチンでの白血病由来細胞の使用 |
| US20250262293A1 (en) | 2020-07-07 | 2025-08-21 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
| IL299764A (en) | 2020-07-10 | 2023-03-01 | Precigen Inc | Fusion constructs and methods for using them |
| WO2022009157A1 (en) | 2020-07-10 | 2022-01-13 | Novartis Ag | Lhc165 and spartalizumab combinations for treating solid tumors |
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| JP7819176B2 (ja) | 2020-08-03 | 2026-02-24 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| IL300080A (en) | 2020-08-18 | 2023-03-01 | Onchilles Pharma Inc | Processed porcine pancreatic elastase proteins |
| IL300328A (en) | 2020-08-26 | 2023-04-01 | Regeneron Pharma | Methods for treating cancer by administering a PD-1 inhibitor |
| EP4204095A1 (en) | 2020-08-28 | 2023-07-05 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hepatocellular carcinoma |
| AU2021330087B2 (en) * | 2020-08-31 | 2025-10-23 | Biosion Inc. | PD-1 binding antibodies and uses thereof |
| WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| US20230338587A1 (en) | 2020-08-31 | 2023-10-26 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
| CA3192999A1 (en) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| IL300916A (en) | 2020-08-31 | 2023-04-01 | Bristol Myers Squibb Co | Cell localization signature and immunotherapy |
| WO2022049526A1 (en) | 2020-09-02 | 2022-03-10 | Pharmabcine Inc. | Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer |
| JP2023542490A (ja) | 2020-09-03 | 2023-10-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｐｄ－１阻害剤を投与することによりがん疼痛を処置する方法 |
| CA3188236A1 (en) | 2020-09-14 | 2022-03-17 | Boehringer Ingelheim International Gmbh | Heterologous prime boost vaccine |
| CN116348495A (zh) | 2020-09-18 | 2023-06-27 | 瑞泽恩制药公司 | 结合cd38和/或cd28的抗原结合分子及其用途 |
| MX2023003414A (es) | 2020-09-24 | 2023-04-14 | Merck Sharp & Dohme Llc | Formulaciones estables de anticuerpos programados del receptor de muerte 1 (pd-1) y variantes de hialuronidasa y fragmentos de las mismas y metodos de uso de las mismas. |
| EP4222171A1 (en) | 2020-10-02 | 2023-08-09 | Regeneron Pharmaceuticals, Inc. | Combination of antibodies for treating cancer with reduced cytokine release syndrome |
| US20230374064A1 (en) | 2020-10-05 | 2023-11-23 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
| US20230364127A1 (en) | 2020-10-06 | 2023-11-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
| AR123855A1 (es) | 2020-10-20 | 2023-01-18 | Genentech Inc | Anticuerpos anti-mertk conjugados con peg y métodos de uso |
| AU2021364837A1 (en) | 2020-10-23 | 2023-05-25 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
| KR20230098279A (ko) | 2020-10-28 | 2023-07-03 | 이케나 온콜로지, 인코포레이티드 | Pdx 억제제 또는 독소루비신과 ahr 억제제의 조합 |
| IL302400A (en) | 2020-11-04 | 2023-06-01 | Genentech Inc | Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies |
| CA3196191A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
| CA3196539A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| IL302569A (en) | 2020-11-06 | 2023-07-01 | Novartis Ag | Cd19 binding molecules and uses thereof |
| EP4243852A4 (en) * | 2020-11-13 | 2024-12-11 | Ludwig Institute for Cancer Research Ltd | PD-1 DECOY VARIANTS FOR IMMUNOTHERAPY |
| EP4251128A1 (en) | 2020-11-25 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| CA3202523A1 (en) | 2020-12-02 | 2022-06-09 | Genentech, Inc. | Methods and compositions for neoadjuvant and adjuvant urothelial carcinoma therapy |
| US20220168293A1 (en) | 2020-12-02 | 2022-06-02 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| CA3202374A1 (en) * | 2020-12-15 | 2022-06-23 | Bicara Therapeutics Inc. | Combination therapy for the treatment of cancer |
| WO2022133135A1 (en) | 2020-12-17 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Fabrication of protein-encapsulating microgels |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| MX2023007650A (es) | 2020-12-28 | 2023-09-11 | Bristol Myers Squibb Co | Metodos de tratamiento de tumores. |
| WO2022146947A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| CN116761880A (zh) | 2021-01-20 | 2023-09-15 | 瑞泽恩制药公司 | 改进细胞培养物中的蛋白质滴度的方法 |
| EP4281102A1 (en) | 2021-01-22 | 2023-11-29 | Mendus B.V. | Methods of tumor vaccination |
| JP2024505049A (ja) | 2021-01-29 | 2024-02-02 | ノバルティス アーゲー | 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用 |
| US20240109899A1 (en) | 2021-02-04 | 2024-04-04 | Bristol-Myers Squibb Company | Benzofuran compounds as sting agonists |
| WO2022173931A1 (en) | 2021-02-11 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer by administering a neoadjuvant pd-1 inhibitor |
| CA3207883A1 (en) | 2021-03-03 | 2022-09-09 | Xiaobin Xu | Systems and methods for quantifying and modifying protein viscosity |
| CA3212351A1 (en) | 2021-03-12 | 2022-09-15 | Mendus B.V. | Methods of vaccination and use of cd47 blockade |
| EP4308935A1 (en) | 2021-03-18 | 2024-01-24 | Novartis AG | Biomarkers for cancer and methods of use thereof |
| MX2023011007A (es) | 2021-03-23 | 2023-12-07 | Regeneron Pharma | Metodos para tratar el cancer en pacientes inmunosuprimidos o inmunocomprometidos mediante la administracion de un inhibidor de pd-1. |
| TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
| WO2022204438A1 (en) | 2021-03-25 | 2022-09-29 | Oncxerna Therapeutics, Inc. | Targeted therapies in cancer |
| US20220309215A1 (en) | 2021-03-26 | 2022-09-29 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
| US20240181052A1 (en) | 2021-03-29 | 2024-06-06 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| US12037346B2 (en) | 2021-04-13 | 2024-07-16 | Nuvalent, Inc. | Amino-substituted heteroaryls for treating cancers with EGFR mutations |
| EP4330436A1 (en) | 2021-04-30 | 2024-03-06 | Genentech, Inc. | Therapeutic and diagnostic methods and compositions for cancer |
| AU2021443318A1 (en) | 2021-04-30 | 2023-09-07 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| CN117412767A (zh) | 2021-05-25 | 2024-01-16 | 雪绒花免疫公司 | C-x-c基序趋化因子受体6（cxcr6）结合分子及其使用方法 |
| WO2022251359A1 (en) | 2021-05-26 | 2022-12-01 | Theravance Biopharma R&D Ip, Llc | Bicyclic inhibitors of alk5 and methods of use |
| AU2022286340A1 (en) | 2021-06-01 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202313679A (zh) | 2021-06-03 | 2023-04-01 | 美商欣爍克斯公司 | 包含il-2接合物及pd-1拮抗劑之頭頸癌組合療法 |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| KR20240022608A (ko) | 2021-06-18 | 2024-02-20 | 젠자임 코포레이션 | 항-tgf-베타 항체 제형 및 이의 용도 |
| TW202309078A (zh) | 2021-07-02 | 2023-03-01 | 美商建南德克公司 | 治療癌症之方法及組成物 |
| MX2024000674A (es) | 2021-07-13 | 2024-02-07 | BioNTech SE | Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion. |
| MX2024000406A (es) * | 2021-07-19 | 2024-04-18 | Regeneron Pharma | Combinacion de inhibidores de puntos de control y un virus oncolitico para el tratamiento del cancer. |
| TW202321282A (zh) | 2021-07-19 | 2023-06-01 | 美商再生元醫藥公司 | Il12受體促效劑及其使用方法 |
| JP2024527049A (ja) | 2021-07-28 | 2024-07-19 | ジェネンテック， インコーポレイテッド | がんを治療するための方法及び組成物 |
| CA3224180A1 (en) | 2021-07-28 | 2023-02-02 | F. Hoffmann-La Roche Ag | Methods and compositions for treating cancer |
| JP2024529502A (ja) | 2021-07-30 | 2024-08-06 | オーエヌエー セラピューティクス エセ．エレ． | 抗ｃｄ３６抗体及び癌を治療するためのそれらの使用 |
| WO2023019240A2 (en) | 2021-08-13 | 2023-02-16 | Inovio Pharmaceuticals Inc. | Combination therapy to treat brain cancer |
| JP2024534787A (ja) | 2021-08-16 | 2024-09-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 新規なｉｌ２７受容体アゴニスト及びその使用方法 |
| WO2023039457A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins |
| AU2022348521A1 (en) * | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| TW202327595A (zh) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | 用於治療癌症之氮雜內醯胺化合物的組合 |
| US20250002600A1 (en) | 2021-10-06 | 2025-01-02 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination therapy |
| CN118076894A (zh) | 2021-10-07 | 2024-05-24 | 里珍纳龙药品有限公司 | pH建模和控制的系统及方法 |
| KR20240090312A (ko) | 2021-10-07 | 2024-06-21 | 리제너론 파아마슈티컬스, 인크. | Ph 미터 보정 및 교정 |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| KR20240097864A (ko) | 2021-10-26 | 2024-06-27 | 리제너론 파마슈티칼스 인코포레이티드 | 상이한 온도에서 실험실 용수를 생성하고 실험실 용수를 분배하는 시스템 및 방법 |
| CN118176214A (zh) | 2021-10-29 | 2024-06-11 | 百时美施贵宝公司 | 血液癌症的lag-3拮抗剂疗法 |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
| WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| WO2023086812A1 (en) | 2021-11-11 | 2023-05-19 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
| MX2024005722A (es) | 2021-11-12 | 2024-05-28 | Novartis Ag | Terapia de combinacion para el tratamiento del cancer de pulmon. |
| JP2024541508A (ja) | 2021-11-24 | 2024-11-08 | ジェネンテック， インコーポレイテッド | 治療用インダゾール化合物およびがんの治療における使用方法 |
| US12275745B2 (en) | 2021-11-24 | 2025-04-15 | Genentech, Inc. | Therapeutic compounds and methods of use |
| CN116333118B (zh) * | 2021-12-16 | 2024-04-19 | 徕特康(苏州)生物制药有限公司 | 抗表皮生长因子受体抗体及其制备方法和用途 |
| EP4452327A1 (en) | 2021-12-20 | 2024-10-30 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
| KR20240130137A (ko) | 2022-01-07 | 2024-08-28 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-MUC16 x 항-CD3 항체 단독으로 또는 항-PD-1 항체와의 조합으로 재발성 난소암을 치료하는 방법 |
| MX2024008831A (es) | 2022-01-26 | 2024-07-25 | Bristol Myers Squibb Co | Terapia combinada para carcinoma hepatocelular. |
| WO2023147470A2 (en) | 2022-01-28 | 2023-08-03 | Georgiamune Inc. | Antibodies to programmed cell death protein 1 that are pd-1 agonists |
| WO2023154799A1 (en) | 2022-02-14 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy for treating cancer |
| CA3243885A1 (en) | 2022-02-17 | 2023-08-24 | Vyriad, Inc. | COMBINATIONS OF CHECKPOINT INHIBITORS AND ONCOLYTIC VIRUS FOR CANCER TREATMENT |
| MX2024010310A (es) | 2022-02-25 | 2024-08-28 | Bristol Myers Squibb Co | Terapia de combinacion para carcinoma colorrectal. |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| CA3254481A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | USE OF ANTI-CLAUDIN-1 ANTIBODIES TO INCREASE T LYMPHOCYTE AVAILABILITY |
| JP2025509567A (ja) | 2022-03-17 | 2025-04-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 再発性類上皮肉腫を、二重特異性抗ＭＵＣ１６ｘ 抗ＣＤ３抗体単独で、または抗ＰＤ－１抗体と組み合わせて治療する方法 |
| CA3245647A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | METHODS AND SYSTEMS FOR ANALYZING POLYPEPTIDE VARIANTS |
| JP2025509749A (ja) | 2022-03-18 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ポリペプチドの単離方法 |
| KR20240169042A (ko) | 2022-04-01 | 2024-12-02 | 제넨테크, 인크. | 항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법 |
| CN116925223A (zh) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗pd-1单克隆抗体及其衍生物和用途 |
| US20260042840A1 (en) | 2022-04-07 | 2026-02-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
| IL315992A (en) | 2022-04-08 | 2024-11-01 | Bristol Myers Squibb Co | Identification, classification and quantification of tertiary lymphoid structures using machine learning |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| AU2022458320A1 (en) | 2022-05-11 | 2024-11-28 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| IL316892A (en) | 2022-05-11 | 2025-01-01 | Regeneron Pharma | Multispecific proprotein binding molecules and their uses |
| AU2023269545A1 (en) | 2022-05-12 | 2024-11-14 | BioNTech SE | Binding agents capable of binding to cd27 in combination therapy |
| US20250304714A1 (en) | 2022-05-16 | 2025-10-02 | Regeneron Pharmaceuticals, Inc. | Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies |
| KR20250011926A (ko) | 2022-05-18 | 2025-01-22 | 리제너론 파마슈티칼스 인코포레이티드 | Cd38 및 4-1bb에 결합하는 다중특이적 항원 결합 분자, 및 이의 용도 |
| CA3257280A1 (en) | 2022-05-25 | 2023-11-30 | Msd International Gmbh | COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION |
| EP4532529A1 (en) | 2022-05-27 | 2025-04-09 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
| EP4531916A1 (en) | 2022-06-02 | 2025-04-09 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| US20230391844A1 (en) | 2022-06-04 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
| IL317449A (en) | 2022-06-07 | 2025-02-01 | Genentech Inc | Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist |
| EP4554978A1 (en) | 2022-07-13 | 2025-05-21 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
| IL318252A (en) | 2022-07-19 | 2025-03-01 | Genentech Inc | Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies |
| EP4310197A1 (en) | 2022-07-21 | 2024-01-24 | Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda | Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy |
| WO2024018069A1 (en) | 2022-07-22 | 2024-01-25 | Philogen S.P.A | Anti-cd28 antibodies |
| JP2025526369A (ja) | 2022-07-27 | 2025-08-13 | アストラゼネカ・アクチエボラーグ | Ｐｄ－１／ｐｄ－ｌ１阻害剤を有するインターロイキン１２を発現する組換えウイルスの組み合わせ |
| WO2024030453A1 (en) | 2022-08-02 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies in combination with anti-pd-1 antibodies |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| JP2025529805A (ja) | 2022-08-18 | 2025-09-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | インターフェロンプロタンパク質及びその使用 |
| TW202417012A (zh) * | 2022-08-19 | 2024-05-01 | 美商旗艦先鋒創新公司 | 包含myc調節劑及檢查點抑制劑之組合療法 |
| WO2024049949A1 (en) | 2022-09-01 | 2024-03-07 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
| JP2025533015A (ja) | 2022-09-30 | 2025-10-03 | アレンティス セラピューティクス アクチェンゲゼルシャフト | 薬物抵抗性肝細胞癌の処置 |
| JP2025533075A (ja) | 2022-10-03 | 2025-10-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性ＥＧＦＲｘＣＤ２８抗体単独又は抗ＰＤ－１抗体との併用による癌治療方法 |
| EP4599089A1 (en) | 2022-10-05 | 2025-08-13 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
| WO2024077166A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating lung cancer |
| TW202426505A (zh) | 2022-10-25 | 2024-07-01 | 美商建南德克公司 | 癌症之治療及診斷方法 |
| KR20250099224A (ko) | 2022-11-01 | 2025-07-01 | 하이델베르크 파마 리서치 게엠베하 | 항-gucy2c 항체 및 이의 용도 |
| EP4626446A1 (en) | 2022-12-01 | 2025-10-08 | BioNTech SE | Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy |
| AU2023403103A1 (en) | 2022-12-01 | 2025-07-10 | Medimmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
| IL321098A (en) | 2022-12-14 | 2025-07-01 | Astellas Pharma Europe Bv | Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors |
| TW202435942A (zh) | 2022-12-16 | 2024-09-16 | 美商里珍納龍藥品有限公司 | 評估層析管柱完整性的方法及系統 |
| AU2023408612A1 (en) | 2022-12-20 | 2025-07-03 | BioNTech SE | Methods of treating pancreatic cancer with a pd-1 axis binding antagonist and an rna vaccine |
| IL321575A (en) | 2022-12-21 | 2025-08-01 | Bristol Myers Squibb Co | Combination therapy for lung cancer |
| CN120858108A (zh) | 2023-01-06 | 2025-10-28 | 拉森医疗公司 | 抗il-18bp抗体 |
| WO2024148243A1 (en) | 2023-01-06 | 2024-07-11 | Lassen Therapeutics 1, Inc. | Anti-il-18bp antibodies |
| WO2024150177A1 (en) | 2023-01-11 | 2024-07-18 | Advesya | Treatment methods for solid tumors |
| US20240270836A1 (en) | 2023-01-13 | 2024-08-15 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| TW202445126A (zh) | 2023-01-25 | 2024-11-16 | 美商再生元醫藥公司 | 基於質譜法之體內共表現抗體之表徵 |
| JP2026504180A (ja) | 2023-01-30 | 2026-02-03 | カイマブ・リミテッド | 抗体 |
| TW202445138A (zh) | 2023-02-01 | 2024-11-16 | 美商再生元醫藥公司 | 用於生物巨分子分析之具質譜法的不對稱流場流分離 |
| WO2024165403A1 (en) | 2023-02-06 | 2024-08-15 | Philogen S.P.A. | Anti-cea antibodies |
| WO2024178213A2 (en) | 2023-02-22 | 2024-08-29 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| WO2024175699A1 (en) | 2023-02-23 | 2024-08-29 | Imcheck Therapeutics | Combination of btn3a activating antibody and immune checkpoint inhibitors |
| JP2026507123A (ja) | 2023-02-28 | 2026-02-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｔ細胞活性化剤およびその使用方法 |
| KR20250155054A (ko) | 2023-03-13 | 2025-10-29 | 리제너론 파마슈티칼스 인코포레이티드 | 흑색종 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용 |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2024209072A1 (en) | 2023-04-06 | 2024-10-10 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 for treating cancer |
| WO2024223299A2 (en) | 2023-04-26 | 2024-10-31 | Isa Pharmaceuticals B.V. | Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor |
| TW202508625A (zh) | 2023-05-01 | 2025-03-01 | 美商再生元醫藥公司 | 使用苯酚或苯甲醇之多劑量抗體藥物產品 |
| TW202448949A (zh) | 2023-05-05 | 2024-12-16 | 美商建南德克公司 | 用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥 |
| IL324490A (en) | 2023-05-10 | 2026-01-01 | Genentech Inc | Methods and preparations for treating cancer |
| TW202509071A (zh) | 2023-05-12 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 能夠與ｏｘ４０結合之抗體、其變異體及其用途 |
| WO2024236048A1 (en) | 2023-05-16 | 2024-11-21 | Nh Theraguix | Combination therapy for treating tumors with radiotherapy |
| WO2024263195A1 (en) | 2023-06-23 | 2024-12-26 | Genentech, Inc. | Methods for treatment of liver cancer |
| CN121605130A (zh) | 2023-06-23 | 2026-03-03 | 感应检查疗法公司 | 靶向btn3a和pd-1/pd-l1抑制轴的双特异性抗体 |
| WO2024263904A1 (en) | 2023-06-23 | 2024-12-26 | Genentech, Inc. | Methods for treatment of liver cancer |
| WO2025024257A1 (en) | 2023-07-21 | 2025-01-30 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| WO2025021073A1 (zh) | 2023-07-21 | 2025-01-30 | 江苏迈威康新药研发有限公司 | 抗Nectin4抗体药物偶联物和抗PD-1抗体的药物组合以及其用途 |
| CN121604974A (zh) | 2023-08-02 | 2026-03-03 | 瑞泽恩制药公司 | 用双特异性抗psma x抗CD28抗体治疗转移性去势抵抗性前列腺癌的方法 |
| WO2025030044A1 (en) | 2023-08-02 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | Methods of treating clear cell renal cell carcinoma with bispecific anti-psma x anti-cd28 antibodies |
| CN121712571A (zh) | 2023-08-15 | 2026-03-20 | 百时美施贵宝公司 | 陶瓷羟基磷灰石色谱流通法 |
| WO2025049277A1 (en) | 2023-08-25 | 2025-03-06 | Genentech, Inc. | Methods and compositions for treating non-small cell lung cancer comprising an anti-tigit antagonist antibody and a pd-1 axis binding antagonist |
| US20250086164A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
| WO2025064403A2 (en) | 2023-09-18 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| US20250109905A1 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| US20250108173A1 (en) | 2023-10-02 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Drug delivery device safety system |
| US20250114468A1 (en) | 2023-10-09 | 2025-04-10 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine |
| WO2025085404A1 (en) | 2023-10-16 | 2025-04-24 | Genentech, Inc. | Diagnostic and therapeutic methods for treating lung cancer |
| US20250129117A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| US20250145662A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025106469A1 (en) | 2023-11-14 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Engineered heavy chain variable domains and uses thereof |
| WO2025106736A2 (en) | 2023-11-15 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer |
| TW202539732A (zh) * | 2023-11-29 | 2025-10-16 | 美商再生元醫藥公司 | 以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法 |
| TW202540189A (zh) | 2023-11-30 | 2025-10-16 | 德商生物新技術公司 | 在組合療法中能夠結合ｏｘ４０之抗體 |
| WO2025117889A2 (en) | 2023-11-30 | 2025-06-05 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer by administering a combination therapy including a neoadjuvant pd-1 inhibitor |
| US20250179137A1 (en) | 2023-12-05 | 2025-06-05 | Regeneron Pharmaceuticals, Inc. | Il18 receptor agonists and methods of use thereof |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| TW202541837A (zh) | 2023-12-08 | 2025-11-01 | 日商安斯泰來製藥公司 | 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法 |
| TW202542187A (zh) | 2023-12-12 | 2025-11-01 | 美商再生元醫藥公司 | 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法 |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
| WO2025155607A1 (en) | 2024-01-16 | 2025-07-24 | Genentech, Inc. | Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025174933A1 (en) | 2024-02-14 | 2025-08-21 | Genentech, Inc. | Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025184208A1 (en) | 2024-02-27 | 2025-09-04 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| US12521446B2 (en) | 2024-02-27 | 2026-01-13 | Bristol-Myers Squibb Company | Anti-CEACAM5 antibody drug conjugates |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| WO2025199243A1 (en) | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Trivalent multispecific binding molecules and methods of use thereof |
| WO2025226695A1 (en) | 2024-04-23 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| WO2025232879A1 (en) | 2024-05-10 | 2025-11-13 | Cytocares (Shanghai) Inc. | Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof |
| WO2025245489A1 (en) | 2024-05-24 | 2025-11-27 | Bristol-Myers Squibb Company | Treatment of tumors in subjects having fgl-1 positive samples |
| US20250376524A1 (en) | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Tetravalent multispecific binding molecules and methods of use thereof |
| WO2025257588A1 (en) | 2024-06-10 | 2025-12-18 | Affimed Gmbh | Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
Family Cites Families (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| CA2383424C (en) | 1999-08-23 | 2011-02-15 | Gordon Freeman | Novel b7-4 molecules and uses therefor |
| WO2001014557A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| EP3225632B1 (en) | 1999-11-30 | 2020-05-06 | Mayo Foundation for Medical Education and Research | Antibodies binding to b7-h1, a novel immunoregulatory molecule |
| AU7309601A (en) | 2000-06-28 | 2002-01-08 | Genetics Inst | Pd-l2 molecules: novel pd-1 ligands and uses therefor |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) * | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AR036993A1 (es) | 2001-04-02 | 2004-10-20 | Wyeth Corp | Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas |
| AU2002258941A1 (en) | 2001-04-20 | 2002-11-05 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| EP2206517B1 (en) | 2002-07-03 | 2023-08-02 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| JP2004104681A (ja) | 2002-09-12 | 2004-04-02 | Renesas Technology Corp | 入力バッファ回路 |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| CN1753912B (zh) * | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) * | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| CN1942483B (zh) | 2004-04-13 | 2012-09-26 | 弗·哈夫曼-拉罗切有限公司 | 抗p型选凝素抗体 |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| ES2720160T3 (es) * | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| AU2006262232A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | CD19 antibodies and their uses |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| WO2007100098A1 (ja) | 2006-03-03 | 2007-09-07 | Kyoto University | 細胞表面機能分子の細胞外領域多量体 |
| RS52176B (sr) | 2006-06-02 | 2012-08-31 | Regeneron Pharmaceuticals Inc. | Antitela visokog afiniteta prema humanom il-6 receptoru |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| WO2009024531A1 (en) | 2007-08-17 | 2009-02-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating and diagnosing hematologic malignancies |
| EP2195342A1 (en) | 2007-09-07 | 2010-06-16 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| EP2242773B1 (en) | 2008-02-11 | 2017-06-14 | Cure Tech Ltd. | Monoclonal antibodies for tumor treatment |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| KR101001360B1 (ko) | 2008-06-16 | 2010-12-14 | (주)기가레인 | 전자 기기의 접지에 전기적으로 연결되는 인쇄회로기판 |
| RS54233B1 (sr) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Kompozicije pd-1 antagonista i postupci za njihovu primenu |
| US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| AU2009290543B2 (en) | 2008-09-12 | 2015-09-03 | Oxford University Innovation Limited | PD-1 specific antibodies and uses thereof |
| BRPI0919377A2 (pt) | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| KR101050829B1 (ko) | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
| KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| EP2482849B1 (en) | 2009-09-30 | 2018-06-06 | Memorial Sloan-Kettering Cancer Center | Combination immunotherapy for the treatment of cancer |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| CA2791930A1 (en) | 2010-03-11 | 2011-09-15 | Kerry Louise Tyson | Pd-1 antibody |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| CN107090029B (zh) | 2010-11-11 | 2021-07-13 | 港大科桥有限公司 | 可溶性 pd-1变体、融合构建体及其用途 |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| JP6240600B2 (ja) | 2011-07-24 | 2017-11-29 | キュアテク リミテッド | ヒト化免疫モノクローナル抗体の変異体 |
| EA026924B1 (ru) | 2011-08-01 | 2017-05-31 | Дженентек, Инк. | Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek |
| CN114891797A (zh) * | 2011-10-28 | 2022-08-12 | 瑞泽恩制药公司 | T细胞受体基因修饰小鼠 |
| KR101981873B1 (ko) | 2011-11-28 | 2019-05-23 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| GB201120527D0 (en) | 2011-11-29 | 2012-01-11 | Ucl Business Plc | Method |
| HK1203528A1 (zh) | 2012-01-27 | 2015-10-30 | Gliknik Inc. | 包含igg2鉸鏈結構域的融合蛋白 |
| SMT201800395T1 (it) * | 2012-03-16 | 2018-09-13 | Regeneron Pharma | Anticorpi a catena leggera ingegnerizzati con istidina e roditori modificati geneticamente per la generazione degli stessi |
| EP3511343A1 (en) | 2012-05-04 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use |
| WO2013169693A1 (en) | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| US20130303250A1 (en) | 2012-05-11 | 2013-11-14 | Ryan Moore | Method of Playing a Card Game |
| US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
| RU2689760C2 (ru) | 2012-05-31 | 2019-05-30 | Дженентек, Инк. | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| KR102130865B1 (ko) | 2012-10-02 | 2020-08-05 | 브리스톨-마이어스 스큅 컴퍼니 | 암을 치료하기 위한 항-kir 항체와 항-pd-1 항체의 조합물 |
| EP2911669B1 (en) | 2012-10-26 | 2024-04-10 | The University of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CN105073135A (zh) | 2013-02-22 | 2015-11-18 | 库瑞瓦格有限责任公司 | 疫苗接种和抑制pd-1途径的组合 |
| SMT201700530T1 (it) | 2013-03-14 | 2018-01-11 | Bristol Myers Squibb Co | Combinazione di agonista di dr5 e antagonista anti-pd-1 e metodi d'uso |
| KR20250091304A (ko) | 2013-03-15 | 2025-06-20 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| KR102243062B1 (ko) | 2013-05-02 | 2021-04-21 | 아납티스바이오, 아이엔씨. | 예정된 사멸-1에 대한 항체 |
| WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| AU2014290069B2 (en) | 2013-07-16 | 2019-01-03 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors |
| CN105682683A (zh) | 2013-08-02 | 2016-06-15 | 阿杜罗生物科技控股有限公司 | 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激 |
| JP6586087B2 (ja) | 2013-08-20 | 2019-10-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| SI3508502T1 (sl) | 2013-09-20 | 2023-07-31 | Bristol-Myers Squibb Company | Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| SI3049441T1 (sl) | 2013-09-27 | 2020-03-31 | F. Hoffmann-La Roche Ag | Formulacije protiteles proti PD-L1 |
| KR102225489B1 (ko) | 2013-12-17 | 2021-03-10 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| US10092645B2 (en) | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| UY36351A (es) | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| AU2016233495B2 (en) | 2015-03-13 | 2022-02-24 | Cytomx Therapeutics, Inc | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof |
| CN114591433A (zh) * | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| MA44146B1 (fr) | 2015-12-22 | 2023-10-31 | Regeneron Pharma | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer |
| US11603407B2 (en) * | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
-
2015
- 2015-01-21 TW TW104101891A patent/TWI681969B/zh active
- 2015-01-23 CA CA3207270A patent/CA3207270A1/en active Pending
- 2015-01-23 NZ NZ722342A patent/NZ722342A/en unknown
- 2015-01-23 HU HUE15703187A patent/HUE056332T2/hu unknown
- 2015-01-23 SG SG11201605482SA patent/SG11201605482SA/en unknown
- 2015-01-23 CA CA2936075A patent/CA2936075C/en active Active
- 2015-01-23 PT PT157031873T patent/PT3097119T/pt unknown
- 2015-01-23 LT LTEPPCT/US2015/012589T patent/LT3097119T/lt unknown
- 2015-01-23 US US14/603,776 patent/US9987500B2/en active Active
- 2015-01-23 AU AU2015209233A patent/AU2015209233B2/en active Active
- 2015-01-23 RS RS20211336A patent/RS62507B1/sr unknown
- 2015-01-23 KR KR1020167022944A patent/KR102337042B1/ko active Active
- 2015-01-23 WO PCT/US2015/012589 patent/WO2015112800A1/en not_active Ceased
- 2015-01-23 EP EP15703187.3A patent/EP3097119B1/en active Active
- 2015-01-23 MX MX2016009554A patent/MX385545B/es unknown
- 2015-01-23 HR HRP20211794TT patent/HRP20211794T1/hr unknown
- 2015-01-23 KR KR1020217039773A patent/KR20210152583A/ko not_active Ceased
- 2015-01-23 CN CN202110538997.6A patent/CN113248614A/zh active Pending
- 2015-01-23 SM SM20210669T patent/SMT202100669T1/it unknown
- 2015-01-23 PL PL15703187T patent/PL3097119T3/pl unknown
- 2015-01-23 UY UY0001035964A patent/UY35964A/es not_active Application Discontinuation
- 2015-01-23 SI SI201531692T patent/SI3097119T1/sl unknown
- 2015-01-23 BR BR122022010183-6A patent/BR122022010183B1/pt active IP Right Grant
- 2015-01-23 CN CN201580005698.9A patent/CN106068275B/zh active Active
- 2015-01-23 EP EP21185778.4A patent/EP3967710A1/en active Pending
- 2015-01-23 MY MYPI2016702408A patent/MY176475A/en unknown
- 2015-01-23 EA EA201691482A patent/EA034770B8/ru unknown
- 2015-01-23 UA UAA201608946A patent/UA122666C2/uk unknown
- 2015-01-23 JP JP2016548008A patent/JP6425730B2/ja active Active
- 2015-01-23 ES ES15703187T patent/ES2888224T3/es active Active
- 2015-01-23 DK DK15703187.3T patent/DK3097119T3/da active
-
2016
- 2016-07-04 PH PH12016501330A patent/PH12016501330B1/en unknown
- 2016-07-18 IL IL246818A patent/IL246818B/en active IP Right Grant
- 2016-07-22 MX MX2021003436A patent/MX2021003436A/es unknown
- 2016-07-22 MX MX2021009852A patent/MX2021009852A/es unknown
- 2016-07-22 CL CL2016001871A patent/CL2016001871A1/es unknown
-
2018
- 2018-02-26 US US15/905,685 patent/US10737113B2/en active Active
- 2018-10-22 JP JP2018198310A patent/JP6711883B2/ja active Active
-
2019
- 2019-07-02 IL IL267798A patent/IL267798B/en active IP Right Grant
-
2020
- 2020-05-26 JP JP2020091219A patent/JP7174009B2/ja active Active
- 2020-07-02 US US16/919,296 patent/US20200330794A1/en not_active Abandoned
-
2021
- 2021-11-24 CY CY20211101017T patent/CY1124747T1/el unknown
-
2022
- 2022-08-03 JP JP2022123661A patent/JP7562606B2/ja active Active
-
2024
- 2024-04-24 US US18/644,357 patent/US20240316361A1/en active Pending
- 2024-09-24 JP JP2024164717A patent/JP2024178339A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250092139A1 (en) | Human antibodies to pd-l1 | |
| US20240316361A1 (en) | Human Antibodies To PD-1 | |
| HK40070794A (en) | Human antibodies to pd-1 | |
| HK1230213B (en) | Human antibodies to pd-l1 | |
| HK1230213A1 (en) | Human antibodies to pd-l1 | |
| NZ721656B2 (en) | Human antibodies to pd-l1 | |
| HK1228406B (en) | Human antibodies to pd-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2024 BY ANAQUA SERVICES Effective date: 20221220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2025 BY ANAQUA SERVICES Effective date: 20231220 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2026 BY ANAQUA SERVICES Effective date: 20241219 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2027 BY ANAQUA SERVICES Effective date: 20251217 |